沃替西汀可致尿美沙酮免疫检测假阳性
该研究通过加标实验和七例患者尿样,发现服用常规剂量沃替西汀的患者尿样在Roche KIMS美沙酮II检测中呈阳性,但GC/MS确认及另两种免疫平台均为阴性,提示沃替西汀及其代谢物可干扰该检测。
要点
- 服用常规剂量沃替西汀的患者尿样在Roche美沙酮免疫检测中可能出现假阳性。
- 假阳性可出现在尿中未检出母药的情况下,与代谢物高交叉反应有关。
- 对接受阿片类成瘾治疗且合并情绪障碍的患者,应警惕此干扰。
核心结论
- 沃替西汀使用可能导致Roche KIMS美沙酮II尿液免疫检测出现假阳性。
研究设计与样本
- 加标实验使用沃替西汀母药浓度7500 ng/ml,并检测七例服用常规剂量沃替西汀患者的尿样。
主要发现
- 七例患者尿样在Roche检测中呈美沙酮阳性,但GC/MS确认及另两种免疫平台均为阴性。
- 由于沃替西汀的药代动力学及MDN2检测中某代谢物高交叉反应,即使尿中无可检测母药也可能出现假阳性。
临床怎么用
- 临床医生应知晓沃替西汀对Roche KIMS美沙酮II尿液检测的干扰,对阳性结果需用确认方法复核。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Urine immunoassays are frequently employed for methadone screening because they are relatively inexpensive and widely available. However, immunoassays are notoriously prone to false positives. We report that the use of vortioxetine (Trintellix® in the USA and Canada, Brintellix® worldwide) could cause false positives in the Roche KIMS Methadone II Urine immunoassay (MDN2). METHODS: We performed a spiking study using a parent drug vortioxetine concentration of 7500 ng/ml. RESULTS: Urine specimens from seven patients on typical vortioxetine doses tested positive for methadone in the Roche assay but negative for methadone in a confirmatory (GC/MS) assay and two other immunoassay platforms. Because of the pharmacokinetics of vortioxetine and the high cross-reactivity of a metabolite in the MDN2 assay, routine use of the drug could cause false positives even without detectible parent drug in the urine. CONCLUSIONS: Vortioxetine is commonly prescribed for mood disorders, which have high prevalence in patients treated for opioid addiction. For that reason, it is important that clinicians are aware of this interference.
引用
- Uljon S, Kataria Y, Flood JG, et al. Vortioxetine use may cause false positive immunoassay results for urine methadone. Clin Chim Acta. 2019. PMID: 31469980. doi:10.1016/j.cca.2019.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。